54 related articles for article (PubMed ID: 38664331)
41. Analysis of circulating tumor DNA to monitor metastatic breast cancer.
Dawson SJ; Tsui DW; Murtaza M; Biggs H; Rueda OM; Chin SF; Dunning MJ; Gale D; Forshew T; Mahler-Araujo B; Rajan S; Humphray S; Becq J; Halsall D; Wallis M; Bentley D; Caldas C; Rosenfeld N
N Engl J Med; 2013 Mar; 368(13):1199-209. PubMed ID: 23484797
[TBL] [Abstract][Full Text] [Related]
42. Preoperative chemoradiotherapy for esophageal or junctional cancer.
van Hagen P; Hulshof MC; van Lanschot JJ; Steyerberg EW; van Berge Henegouwen MI; Wijnhoven BP; Richel DJ; Nieuwenhuijzen GA; Hospers GA; Bonenkamp JJ; Cuesta MA; Blaisse RJ; Busch OR; ten Kate FJ; Creemers GJ; Punt CJ; Plukker JT; Verheul HM; Spillenaar Bilgen EJ; van Dekken H; van der Sangen MJ; Rozema T; Biermann K; Beukema JC; Piet AH; van Rij CM; Reinders JG; Tilanus HW; van der Gaast A;
N Engl J Med; 2012 May; 366(22):2074-84. PubMed ID: 22646630
[TBL] [Abstract][Full Text] [Related]
43. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907).
Ando N; Kato H; Igaki H; Shinoda M; Ozawa S; Shimizu H; Nakamura T; Yabusaki H; Aoyama N; Kurita A; Ikeda K; Kanda T; Tsujinaka T; Nakamura K; Fukuda H
Ann Surg Oncol; 2012 Jan; 19(1):68-74. PubMed ID: 21879261
[TBL] [Abstract][Full Text] [Related]
44. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
Eisenhauer EA; Therasse P; Bogaerts J; Schwartz LH; Sargent D; Ford R; Dancey J; Arbuck S; Gwyther S; Mooney M; Rubinstein L; Shankar L; Dodd L; Kaplan R; Lacombe D; Verweij J
Eur J Cancer; 2009 Jan; 45(2):228-47. PubMed ID: 19097774
[TBL] [Abstract][Full Text] [Related]
45. Circulating mutant DNA to assess tumor dynamics.
Diehl F; Schmidt K; Choti MA; Romans K; Goodman S; Li M; Thornton K; Agrawal N; Sokoll L; Szabo SA; Kinzler KW; Vogelstein B; Diaz LA
Nat Med; 2008 Sep; 14(9):985-90. PubMed ID: 18670422
[TBL] [Abstract][Full Text] [Related]
46. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.
Lordick F; Ott K; Krause BJ; Weber WA; Becker K; Stein HJ; Lorenzen S; Schuster T; Wieder H; Herrmann K; Bredenkamp R; Höfler H; Fink U; Peschel C; Schwaiger M; Siewert JR
Lancet Oncol; 2007 Sep; 8(9):797-805. PubMed ID: 17693134
[TBL] [Abstract][Full Text] [Related]
47. Clinical significance of the second cycle response to cisplatin-based chemotherapy as preoperative treatment for esophageal squamous cell carcinoma.
Akita H; Doki Y; Miyata H; Hirao T; Yano M; Takachi K; Miyashiro I; Sasaki Y; Ishikawa O; Ohigashi H; Imaoka S
J Surg Oncol; 2006 Apr; 93(5):401-9. PubMed ID: 16550577
[TBL] [Abstract][Full Text] [Related]
48. Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice: analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resistance protein, prostaglandin E synthetase, and glutathione-S-transferase-alpha (GST)-alpha, GST-mu, and GST-pi.
Mathieu A; Remmelink M; D'Haene N; Penant S; Gaussin JF; Van Ginckel R; Darro F; Kiss R; Salmon I
Cancer; 2004 Oct; 101(8):1908-18. PubMed ID: 15386340
[TBL] [Abstract][Full Text] [Related]
49. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment.
Wieder HA; Brücher BL; Zimmermann F; Becker K; Lordick F; Beer A; Schwaiger M; Fink U; Siewert JR; Stein HJ; Weber WA
J Clin Oncol; 2004 Mar; 22(5):900-8. PubMed ID: 14990646
[TBL] [Abstract][Full Text] [Related]
50. Utility of Initial Tumor Reduction as a Prognostic Factor in Esophageal Squamous Cell Cancer Patients Undergoing Neoadjuvant Chemotherapy Followed by Surgery : A Retrospective Cohort Study.
Hagi T; Shiraishi O; Nakanishi T; Kohda M; Hiraki Y; Kato H; Yasuda A; Shinkai M; Imano M; Yasuda T
Ann Surg Oncol; 2024 Apr; ():. PubMed ID: 38664331
[TBL] [Abstract][Full Text] [Related]
51. Prognostic Factors for Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery.
Kitasaki N; Hamai Y; Emi M; Kurokawa T; Yoshikawa T; Hirohata R; Ohsawa M; Okada M
In Vivo; 2022; 36(6):2852-2860. PubMed ID: 36309376
[TBL] [Abstract][Full Text] [Related]
52. Docetaxel, Cisplatin, and 5-FU Triplet Therapy as Conversion Therapy for Locoregionally Advanced Unresectable Esophageal Squamous Cell Carcinoma.
Chan WL; Choi CW; Wong IY; Tsang TH; Lam AT; Tse RP; Chan KK; Wong C; Law BT; Cheung EE; Chan SY; Lam KO; Kwong D; Law S
Ann Surg Oncol; 2023 Feb; 30(2):861-870. PubMed ID: 36307666
[TBL] [Abstract][Full Text] [Related]
53.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
54.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
